Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024;17(1):111-116.
doi: 10.2174/1874471016666230829100703.

An Investigation of the Relationship Between 18F-FDG PET/CT Parameters of Primary Tumors and Lymph Node Metastasis in Resectable Non-small Cell Lung Cancer

Affiliations
Free article

An Investigation of the Relationship Between 18F-FDG PET/CT Parameters of Primary Tumors and Lymph Node Metastasis in Resectable Non-small Cell Lung Cancer

Ozan Kandemir et al. Curr Radiopharm. 2024.
Free article

Abstract

Background: Mediastinal lymph node metastasis is an important prognostic factor in non-small cell lung cancer (NSCLC) patients without distant metastases. 18F-2-fluoro-2-deoxy-Dglucose Positron Emission Tomography/Computed Tomography (18F-FDG PET/CT) is recommended for detecting and staging lymph nodes and distant metastases in NSCLC patients.

Objective: This study aims to investigate whether maximum standardized uptake (SUVmax), mean standardized uptake (SUVmean), metabolic tumor volume (MTV), and tumor lesion glycolysis (TLG) values of the primary tumor measured by 18F-FDG PET/CT in resectable NSCLC can predict preoperative lymph node metastasis.

Methods: This retrospective study included eighty NSCLC patients who underwent preoperative Positron Emission Tomography/Computed Tomography (PET/CT) for diagnosis and staging. The patients were stage I-III and had no distant metastases. Tumor metabolic parameters such as SUVmax, SUVmean, MTV, and TLG at PET/CT imaging were measured for preoperative diagnosis and staging, and the postoperative pathology results of the patients were examined. The pathology results divided patients with and without lymph node metastasis into two groups. The groups were compared with the student's t-test and chi-square test regarding 18F-FDG PET/CT tumor metabolic parameters and other parameters.

Results: Fifteen (18.8%) patients were female, and 65 (81.3%) were male. According to the postoperative pathology results, while 30 (37.5%) patients had lymph node metastasis, 50 (62.5%) did not. There was a significant difference between the groups regarding tumor SUVmax and SUVmean values (p = 0.036, p = 0.045). Overall survival in the N0 group was significantly higher than in the N1 + N2 group (p = 0.034); median survival was 30.2 months in N0 cases and 27.3 months in N1 and N2 groups.

Conclusion: SUVmax and SUVmean values are significantly higher in patients with lymph node metastases than in patients without lymph node metastases, and this finding may provide useful information for predicting lymph node metastasis in patients with resectable NSCLC.

Keywords: 18F-2-fluoro-2-deoxy-D-glucose; Non-small cell lung cancer; lymph node metastasis; maximum standardized uptake value; mean standardized uptake.; positron emission tomography.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Thai A.A.; Solomon B.J.; Sequist L.V.; Gainor J.F.; Heist R.S.; Lung cancer. Lancet 2021,398(10299),535-554 - DOI - PubMed
    1. Hua J.; Li L.; Liu L.; Liu Q.; Liu Y.; Chen X.; The diagnostic value of metabolic, morphological and heterogeneous parameters of 18F-FDG PET/CT in mediastinal lymph node metastasis of non–small cell lung cancer. Nucl Med Commun 2021,42(11),1247-1253 - DOI - PubMed
    1. Ettinger D.S.; Wood D.E.; Aisner D.L.; Akerley W.; Bauman J.; Chirieac L.R.; D’Amico T.A.; DeCamp M.M.; Dilling T.J.; Dobelbower M.; Doebele R.C.; Govindan R.; Gubens M.A.; Hennon M.; Horn L.; Komaki R.; Lackner R.P.; Lanuti M.; Leal T.A.; Leisch L.J.; Lilenbaum R.; Lin J.; Loo B.W.; Martins R.; Otterson G.A.; Reckamp K.; Riely G.J.; Schild S.E.; Shapiro T.A.; Stevenson J.; Swanson S.J.; Tauer K.; Yang S.C.; Gregory K.; Hughes M.; Non-small cell lung cancer, Version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2017,15(4),504-535 - DOI - PubMed
    1. Farsad M.; FDG PET/CT in the staging of lung cancer. Curr Radiopharm 2020,13(3),195-203 - DOI - PubMed
    1. Suh Y.J.; Park C.M.; Han K.; Jeon S.K.; Kim H.; Hwang E.J.; Lee J.H.; Paeng J.C.; Lee C.H.; Kim Y.T.; Goo J.M.; Utility of FDG PET/CT for preoperative staging of non -small cell lung cancers manifesting as subsolid nodules with a solid portion of 3 cm or smaller. AJR Am J Roentgenol 2020,214(3),514-523 - DOI - PubMed

MeSH terms

Substances